Molecular Partners (NASDAQ:MOLN) Stock Price Up 5% - Still a Buy?

Key Points

• Stock up 5%: Molecular Partners' shares rose about 5% to $4.41 (intraday high $4.53) with trading volume (~6,737 shares) up 154% versus the average.
• Analyst views are mixed — two Buy, one Hold and one Sell — resulting in a consensus rating of "Hold" and a target price of $8.38.
• The clinical-stage biopharma has a market cap of $178.1M, reported a quarterly loss (EPS -$0.41 vs. -$0.38 expected) and is forecast to post roughly -1.4 EPS for the year while developing DARPin® therapies across infectious disease, ophthalmology and oncology.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report)'s stock price was up 5% during trading on Monday . The stock traded as high as $4.53 and last traded at $4.41. Approximately 6,737 shares changed hands during mid-day trading, an increase of 154% from the average daily volume of 2,649 shares. The stock had previously closed at $4.20.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Molecular Partners in a research report on Friday, April 10th. TD Cowen restated a "buy" rating on shares of Molecular Partners in a research report on Monday, March 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Molecular Partners in a research note on Monday, March 16th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Molecular Partners presently has an average rating of "Hold" and a consensus target price of $8.38.

Molecular Partners Stock Up 5.0%

The firm has a market capitalization of $178.08 million, a price-to-earnings ratio of -2.22 and a beta of 1.11. The business's fifty day moving average is $4.52 and its 200 day moving average is $4.27.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.03). Equities research analysts expect that Molecular Partners AG Sponsored ADR will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,311 shares of the company's stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors and hedge funds.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company's technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company's development pipeline spans infectious diseases, ophthalmology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.